Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

BACKGROUND: Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed to capture both typical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulkey, Flora, Theoret, Marc R, Keegan, Patricia, Pazdur, Richard, Sridhara, Rajeshwari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057528/
https://www.ncbi.nlm.nih.gov/pubmed/32107275
http://dx.doi.org/10.1136/jitc-2019-000146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057528/
https://www.ncbi.nlm.nih.gov/pubmed/32107275
http://dx.doi.org/10.1136/jitc-2019-000146

Ejemplares similares